Oncologie préclinique

Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities. 

When your research has the potential to save lives, you deserve a partner with the oncology pharmacology knowledge, breadth of tools and experience to move life-changing drug candidates through non-GLP, preclinical development and oncology clinical trials quickly and efficiently.  

We've helped hundreds of companies discover their next life-improving compound. 

Preclinical oncology research services

Cell Lines & Tumor Models

Cancer growth curves and cell line list

Immunotherapy & Adoptive Cell Therapy Support

We offer over 30 different syngeneic tumor models, from both solid and disseminated origins, to provide you with many choices to further your immuno-oncology research. We are continually improving and expanding adoptive cell therapy capabilities:

Flow Cytometry, Imaging and Radiation

 

For over a decade, we have offered an industry-leading array of in vivo imaging modalities for optimum pharmacologic interrogation when needed. Parmi celles-ci :

Immunotherapies for oncology drug development

Preclinical Oncology Resources

Spotlight:

LL/2 : un modèle de tumeur murine immunosuppressive

Le cancer du poumon est le deuxième cancer le plus couramment diagnostiqué chez les hommes et les femmes aux États-Unis et c'est, de loin, la cause la plus fréquente de décès des suites d'un cancer chez les hommes et les femmes. In 2019, the American Cancer Society estimates that 228 150 new cases of lung cancer (116 440 in men and 111 710 in women) will . . . Read more about the LL/2 model

Spotlight:

B16-F10 : un modèle de mélanome murin

Les cancers de la peau comprennent des carcinomes de toutes les couches de la peau, les plus communs étant le carcinome basocellulaire (CBC) et le carcinome à cellules squameuses (CCS). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common. . . . Read more about a murine melanoma model

Poster:

Preclinical Models of Multiple Myeloma

Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow that is invasive and drug resistant. Patients are generally asymptomatic until very late state disease. There are few preclinical models that recapitulate human disease. In this work, we have evaluated the human MM.1S model and the murine 5TGM1 model . . . Read more about the preclinical models of multiple myeloma

Poster:

Caractérisation en profondeur des cellules myéloïdes dans le modèle syngénique murin de carcinome du côlon CT.26 par cytométrie en flux à 10 couleurs

The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function. . . Read more about In-Depth Myeloid Cell Characterization

About Preclinical Oncology

In 2019 Covance welcomed the preclinical pharmacology oncology provider, MI Bioresearch, into the Covance family. You can now access hundreds of cell line assays and tumor models, as well as thousands of potential oncology patients for clinical trials or explore an extensive library of oncology diagnostics

Preclinical Oncology Events